NRIX news

Nurix announced the first patient dosing in a registrational Phase 3 trial for bexobrutideg and received a $700 million upfront payment from Roche, bolstering cash reserves to $1.1 billion.

Nurix Therapeutics announced updated Phase 1a/b clinical trial results showing a 92.9% objective response rate in second-line CLL patients treated with bexobrutideg, with durable responses in heavily pretreated patients and promising activity in earlier treatment lines. The positive data supports ad…

Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, receiving $700 million upfront plus up to $2.3 billion in milestone payments. The partnership combines Nurix's protein degradation technology with Roche's clinical expertise to expand bexo…